In Brief

Lupus nephritis: Phase III ocrelizumab trial halted by infections

  • Subscribe to Nature Reviews Rheumatology for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


  1. 1.

    et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from the randomized, double-blind phase III BELONG study. Arthritis Rheum. doi:10.1002/art.38037

Download references